A comparative pharmacokinetic study of PARP inhibito properties for niraparib efficacy in preclinical tumor m

Oncotarget

9, 37080-37096

DOI: 10.18632/oncotarget.26354

Citation Report

#	Article	IF	Citations
1	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. Neuro-Oncology Advances, 2019, 1, vdz005.	0.4	9
2	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. International Journal of Molecular Sciences, 2019, 20, 3100.	1.8	32
3	Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell, 2019, 177, 1903-1914.e14.	13.5	188
4	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 636-648.	5.1	366
5	Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. Annals of Translational Medicine, 2019, 7, S308-S308.	0.7	0
6	Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Reports, 2019, 12, e230738.	0.2	18
7	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	3.2	66
8	Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis. Shock, 2020, 53, 653-665.	1.0	11
9	Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization. Bioorganic and Medicinal Chemistry, 2020, 28, 115819.	1.4	7
10	Newly diagnosed ovarian cancer: Which first-line treatment?. Cancer Treatment Reviews, 2020, 91, 102111.	3.4	23
11	Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. International Journal of Molecular Sciences, 2020, 21, 4910.	1.8	45
12	Niraparib in the treatment of previously treated advanced ovarian, fallopian tubeÂor primary peritoneal cancer. Future Oncology, 2020, 16, 2701-2711.	1.1	1
13	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma. Oncogenesis, 2020, 9, 80.	2.1	13
14	First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. ESMO Open, 2020, 5, e001110.	2.0	42
15	Investigation of human adipose stem cell-derived nanoparticles as a biomimetic carrier for intracellular drug delivery. Nanoscale, 2020, 12, 24273-24284.	2.8	10
16	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 1206.	1.7	6
17	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. International Journal of Biological Sciences, 2020, 16, 1363-1375.	2.6	22
18	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences, 2020, 21, 4579.	1.8	66

#	Article	IF	Citations
19	Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes. Journal of Clinical Medicine, 2020, 9, 2130.	1.0	24
20	DNA inhibitors for the treatment of brain tumors. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 195-207.	1.5	3
21	Therapeutic Application of PARP Inhibitors in Neuro-Oncology. Trends in Cancer, 2020, 6, 147-159.	3.8	9
22	Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report. BMC Psychiatry, 2020, 20, 171.	1.1	6
23	Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases. Journal of Huntington's Disease, 2021, 10, 203-220.	0.9	21
24	Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report. Annals of Palliative Medicine, 2021, 10, 818-827.	0.5	13
25	The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab015.	0.4	16
26	Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review. Journal of Immunotherapy and Precision Oncology, 2021, 4, 16-20.	0.6	1
27	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e16.	1.0	8
28	The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Japanese Journal of Clinical Oncology, 2021, 51, 693-699.	0.6	4
29	Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. Investigational New Drugs, 2021, 39, 1213-1221.	1.2	6
30	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resistance Updates, 2021, 55, 100744.	6.5	43
31	DNA Damage Repair Genes and Noncoding RNA in High-Grade Gliomas and Its Clinical Relevance. , 0, , .		1
33	Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors. Briefings in Bioinformatics, 2021, 22, .	3.2	5
34	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 773-791.	12.5	198
35	Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gynecologic Oncology, 2021, 162, 163-172.	0.6	18
36	Identification of different side effects between PARP inhibitors and their polypharmacological multiâ€target rationale. British Journal of Clinical Pharmacology, 2022, 88, 742-752.	1.1	38
37	BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme. Biomolecules, 2021, 11, 1188.	1.8	13

#	Article	IF	Citations
38	The evolving role of PARP inhibitors in advanced ovarian cancer. Forum of Clinical Oncology, 2021, 12, 82-104.	0.1	0
39	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer Treatment Reviews, 2021, 99, 102255.	3.4	25
41	Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. American Journal of Case Reports, 2020, 21, e927008.	0.3	5
42	Persistent double strand break accumulation does not precede cell death in an Olaparib-sensitive BRCA-deficient colorectal cancer cell model. Genetics and Molecular Biology, 2020, 43, e20190070.	0.6	6
43	Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review . OncoTargets and Therapy, 2020, Volume 13, 12979-12986.	1.0	7
44	Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistance. Current Drug Targets, 2019, 20, 891-902.	1.0	15
45	New medical approaches in advanced ovarian cancer. Minerva Medica, 2019, 110, 367-384.	0.3	6
46	Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer. Targeted Oncology, 2021, 16, 839-845.	1.7	17
47	Advanced Genomics-Based Approaches for Defining Allograft Rejection With Single Cell Resolution. Frontiers in Immunology, 2021, 12, 750754.	2.2	5
48	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Molecular Pharmaceutics, 2021, 18, 4371-4384.	2.3	6
49	Clinically Relevant Response to Treatment with Olaparib in a Patient with Refractory Multidrug-Resistant Ovarian Cancer and Central Nervous System Involvement: A Case Report. American Journal of Case Reports, 2020, 21, e925990.	0.3	1
50	TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models. American Journal of Cancer Research, 2021, 11, 1632-1645.	1.4	1
51	Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date. Seminars in Radiation Oncology, 2022, 32, 15-28.	1.0	8
52	EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. Acta Neuropathologica, 2022, 143, 1-13.	3.9	17
53	Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors?. Neuro-Oncology Advances, 2022, 4, vdab190.	0.4	6
54	Targeting brain metastases in breast cancer. Cancer Treatment Reviews, 2022, 103, 102324.	3.4	46
55	Clinically Relevant Response to Treatment with Olaparib in a Patient with Refractory Multidrug-Resistant Ovarian Cancer and Central Nervous System Involvement: A Case Report. American Journal of Case Reports, 2020, 21, e925990.	0.3	2
56	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers, 2022, 14, 1003.	1.7	18

#	Article	IF	Citations
57	<scp>XRCC1</scp> counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped <scp>PARP1</scp> from broken <scp>DNA</scp>. Genes To Cells, 2022, 27, 331-344.	0.5	12
58	Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice. European Journal of Pharmaceutical Sciences, 2022, 173, 106177.	1.9	6
59	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. Cells, 2021, 10, 3408.	1.8	4
60	Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. International Journal of Clinical Oncology, 2022, 27, 1001-1012.	1.0	8
61	DNA damage response and repair in the development and treatment of brain tumors. European Journal of Pharmacology, 2022, 924, 174957.	1.7	7
62	Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature. Frontiers in Oncology, 2022, 12, 873198.	1.3	5
63	Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nature Communications, 2022, 13, 2400.	5.8	13
64	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. Molecular Cancer Therapeutics, 2022, 21, 1115-1124.	1.9	3
65	Chromatin dynamics orchestrates DNA repair mechanisms in glioblastoma. International Journal of Neurooncology, 2021, 4, 38.	0.1	0
66	Methods for profiling the target and off-target landscape of PARP inhibitors. Current Research in Chemical Biology, 2022, 2, 100027.	1.4	2
67	The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. Molecular Neurobiology, 2022, 59, 5326-5365.	1.9	13
68	Reconsidering the mechanisms of action of <scp>PARP</scp> inhibitors based on clinical outcomes. Cancer Science, 2022, 113, 2943-2951.	1.7	11
69	Development of Chitosan-Coated PLGA-Based Nanoparticles for Improved Oral Olaparib Delivery: In Vitro Characterization, and In Vivo Pharmacokinetic Studies. Processes, 2022, 10, 1329.	1.3	11
70	Bloodâ€“brain barrier penetration prediction enhanced by uncertainty estimation. Journal of Cheminformatics, 2022, 14, .	2.8	11
71	Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context. Future Oncology, 2022, 18, 2505-2536.	1.1	4
72	Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nature Cancer, 2022, 3, 927-931.	5.7	12
73	Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis. Journal of Clinical Medicine, 2022, 11, 4165.	1.0	3
74	Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. Frontiers in Genetics, 0, 13, .	1.1	4

#	Article	IF	Citations
76	Factors affecting the radiation response in glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.4	6
80	Personalized Treatment in Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2022, , 1-19.	0.0	0
81	Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Clinical Pharmacokinetics, 2022, 61, 1649-1675.	1.6	23
82	Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. Cell Death and Disease, 2022, 13, .	2.7	6
83	Therapeutic Options for Brain Metastases in Gynecologic Cancers. Current Treatment Options in Oncology, 2022, 23, 1601-1613.	1.3	0
84	SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair. Disease Markers, 2022, 2022, 1-11.	0.6	2
85	Niraparib-induced STAT3 inhibition increases its antitumor effects. Frontiers in Oncology, 0, 12, .	1.3	1
86	Parameter estimation of Weibull distribution for the number of days between drug administration and early onset adverse event. Journal of Biopharmaceutical Statistics, 0, , 1-14.	0.4	2
87	Thioparib inhibits homologous recombination repair, activates the <scp>type I IFN</scp> response, and overcomes olaparib resistance. EMBO Molecular Medicine, 2023, 15, .	3.3	6
88	[1,2,4]Triazolo[3,4-b]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes. Journal of Medicinal Chemistry, 2023, 66, 1301-1320.	2.9	3
89	Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular Cancer Therapeutics, 2023, 22, 333-342.	1.9	2
90	Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer. Scientific Reports, 2023, 13, .	1.6	3
91	Transporterâ€'mediated drugâ€'drug interactions involving poly (ADPâ€'ribose) polymerase inhibitors (Review). Oncology Letters, 2023, 25, .	0.8	3
92	Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting. Journal of Clinical Medicine, 2023, 12, 2497.	1.0	0
93	Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. Journal of Controlled Release, 2023, 357, 287-298.	4.8	2
94	Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge. Npj Precision Oncology, 2023, 7, .	2.3	1